tiprankstipranks
Trending News
More News >
TECSYS Inc. J (TSE:TCS)
TSX:TCS

TECSYS Inc. J (TCS) AI Stock Analysis

Compare
117 Followers

Top Page

TSE:TCS

TECSYS Inc. J

(TSX:TCS)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 5.2)
Rating:63Neutral
Price Target:
C$26.00
▼(-16.72% Downside)
The score is driven primarily by solid financial stability (minimal leverage) and a positive earnings-call readthrough (strong SaaS/EBITDA growth with maintained guidance). These positives are tempered by very weak technical momentum (below key moving averages with negative MACD and low RSI) and a demanding valuation (high P/E) alongside soft free-cash-flow growth.
Positive Factors
SaaS Revenue & ARR Growth
Sustained double-digit SaaS revenue and ARR growth reflects a recurring-revenue mix that drives predictable cash flows and higher lifetime value. Maintaining guidance for 20–22% SaaS growth supports durable topline visibility and scalability of subscription economics over the medium term.
High & Improving Gross Margins
Near-50% gross margins, improved to 52% driven by higher SaaS and professional services mix, indicate strong unit economics and pricing power. These margins provide structural room to invest in R&D, go-to-market, and drive sustained EBITDA expansion as SaaS penetration increases.
Very Low Leverage / Strong Balance Sheet
Extremely low leverage and a solid equity base offer financial resilience and flexibility for strategic investments, M&A or cyclical stress. Minimal debt reduces refinancing risk and supports consistent investment in product development and customer success over multiple market cycles.
Negative Factors
Low Net Profit Margin
Despite strong gross margins, the low net margin suggests significant operating costs or non-operating items eroding bottom-line returns. This constrains free cash available for shareholders and limits the pace at which incremental revenue growth translates into durable profitability gains.
Declining Free Cash Flow Growth
Negative FCF growth reduces internal funding for product development and sales expansion, and may force trade-offs in capex or shareholder returns. Even with strong operating cash-to-income, deteriorating FCF trends warrant monitoring for sustainable reinvestment capacity.
Healthcare Concentration & Policy Sensitivity
Heavy exposure to healthcare procurement cycles and policy shifts creates structural booking unpredictability and longer sales cycles. Combined with recent non-core customer attrition, this concentration risk can impede consistent revenue conversion and elongate payback periods for sales investments.

TECSYS Inc. J (TCS) vs. iShares MSCI Canada ETF (EWC)

TECSYS Inc. J Business Overview & Revenue Model

Company DescriptionTecsys Inc. engages in the development, marketing, and sale of enterprise-wide supply chain management software and related services in Canada, the United States, Europe, and internationally. The company offers warehouse management, distribution and transportation management, supply management at point-of-use and order management and fulfillment, as well as financial management and analytics solutions. It also provides implementation, system enhancement, cloud, advisory, consulting, education, training, and maintenance and support services, as well as engages in sale of hardware. The company primarily serves the healthcare systems, automotive and services parts, third-party logistics, retail, and general wholesale distribution industries. Tecsys Inc. was incorporated in 1983 and is headquartered in Montreal, Canada.
How the Company Makes MoneyTECSYS generates revenue primarily through the sale of its software solutions and related services. The company operates on a subscription-based model, where clients pay recurring fees for access to its software, including cloud-based services. Additionally, TECSYS earns revenue from professional services such as implementation, training, and ongoing support. Key revenue streams include licenses for proprietary software, maintenance agreements, and consulting services. The company also benefits from strategic partnerships with technology providers and distributors, which enhance its market reach and expand its customer base, contributing significantly to its earnings.

TECSYS Inc. J Earnings Call Summary

Earnings Call Date:Dec 03, 2025
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Positive
The earnings call reflected strong SaaS and professional services revenue growth, a record adjusted EBITDA, and significant achievements in the healthcare and technology sectors. However, macroeconomic factors and non-core customer attrition presented challenges. Despite these hurdles, the company's robust pipeline and strategic advancements position it well for future growth.
Q2-2026 Updates
Positive Updates
Strong SaaS Revenue Growth
SaaS revenue increased by 22% to $19.7 million in the quarter, with SaaS ARR reaching $81.1 million, up 16% from the same quarter last year.
Record Adjusted EBITDA
The company reported a record adjusted EBITDA in the quarter, up 71% compared to the same quarter last year, reaching $5.0 million.
Professional Services Revenue Growth
Professional services revenue for the second quarter was up 20% from the same quarter last fiscal year to a record $17 million.
New Platform Availability and Industry Recognition
The Elite platform is now available on the AWS marketplace, and Tecsys was recognized as a leader in the 2025 WMS Technology Value Matrix by Nucleus Research.
Healthcare Pipeline Growth
The healthcare pipeline is up about 60% compared to the same time last year, with significant traction in pharmacy markets.
Negative Updates
Impact of Macroeconomic Factors
Long decision cycles slowed bookings due to U.S. healthcare policy changes, tariffs, and uncertainties affecting the supply chain market.
Attrition in Non-Core Customers
Attrition in a small group of non-core customers had a notable impact, with churn being significantly larger than the favorable FX impact.
Company Guidance
During Tecsys' Fiscal Year 2026 Second Quarter Results Conference Call, the company reported robust growth metrics, with SaaS revenue increasing by 22% to $19.7 million and total revenue up by 15% compared to the same quarter last year. Adjusted EBITDA reached a record level, rising by 71% year-over-year to $5.0 million, highlighting the strength of Tecsys' Elite Healthcare Solutions. The SaaS Annual Recurring Revenue (ARR) climbed 16% to $81.1 million, with the core Elite product contributing significantly with a 21% growth. Professional services revenue also saw a notable increase of 20% to $17 million. The gross margin improved to 52%, up from 48% in the previous year, driven by higher SaaS and professional services margins. Despite facing macroeconomic challenges, including the U.S. healthcare policy environment, Tecsys maintained its guidance for full-year SaaS revenue growth of 20% to 22%, total revenue growth of 8% to 10%, and an adjusted EBITDA margin of 8% to 9%. The quarter also marked Tecsys' Elite platform's availability on the AWS marketplace, enhancing their cloud strategy and customer reach.

TECSYS Inc. J Financial Statement Overview

Summary
Solid fundamentals supported by strong gross margin (49.48% TTM) and a very low debt-to-equity ratio (0.009 TTM). Offsetting this are weak net profitability (2.46% net margin TTM) and declining free cash flow growth (-10.68% TTM).
Income Statement
75
Positive
TECSYS Inc. shows a solid revenue growth rate of 3.44% TTM, indicating a positive trajectory in sales. The gross profit margin of 49.48% TTM is strong, reflecting efficient cost management. However, the net profit margin is relatively low at 2.46% TTM, suggesting room for improvement in profitability. The EBIT and EBITDA margins are moderate at 4.25% and 6.36% TTM, respectively, indicating stable operational performance.
Balance Sheet
80
Positive
The company maintains a very low debt-to-equity ratio of 0.009 TTM, highlighting minimal leverage and financial stability. The return on equity is modest at 6.63% TTM, suggesting efficient use of equity capital. The equity ratio stands at 51.00% TTM, indicating a strong equity base relative to total assets, which enhances financial resilience.
Cash Flow
65
Positive
Operating cash flow to net income ratio is 2.73 TTM, showing strong cash generation relative to net income. However, the free cash flow growth rate is negative at -10.68% TTM, indicating a decline in cash available for reinvestment. The free cash flow to net income ratio is 0.63 TTM, suggesting that a significant portion of earnings is converted into free cash flow.
BreakdownTTMDec 2024Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue186.34M171.24M176.45M152.42M137.20M123.10M
Gross Profit94.04M78.39M85.29M66.81M60.31M60.63M
EBITDA13.41M6.21M11.06M7.99M10.11M15.26M
Net Income5.43M1.85M4.46M2.09M4.48M7.19M
Balance Sheet
Total Assets133.71M128.05M140.41M126.92M125.84M129.31M
Cash, Cash Equivalents and Short-Term Investments30.47M35.57M39.29M37.07M43.24M45.85M
Total Debt437.00K2.11M1.32M2.91M14.24M18.76M
Total Liabilities65.54M59.68M69.15M56.48M57.16M62.22M
Stockholders Equity68.17M68.37M71.26M70.44M68.68M67.09M
Cash Flow
Free Cash Flow8.53M3.24M11.16M5.97M2.88M17.58M
Operating Cash Flow14.84M4.86M13.91M7.76M4.94M19.11M
Investing Cash Flow-5.35M-1.47M2.89M-1.11M-2.38M-13.75M
Financing Cash Flow-7.77M-5.76M-8.07M-8.42M-5.31M-7.14M

TECSYS Inc. J Technical Analysis

Technical Analysis Sentiment
Negative
Last Price31.22
Price Trends
50DMA
30.72
Negative
100DMA
32.65
Negative
200DMA
35.86
Negative
Market Momentum
MACD
-1.56
Positive
RSI
28.62
Positive
STOCH
18.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TCS, the sentiment is Negative. The current price of 31.22 is above the 20-day moving average (MA) of 27.69, above the 50-day MA of 30.72, and below the 200-day MA of 35.86, indicating a bearish trend. The MACD of -1.56 indicates Positive momentum. The RSI at 28.62 is Positive, neither overbought nor oversold. The STOCH value of 18.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TCS.

TECSYS Inc. J Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
C$7.87B37.4010.70%14.55%15.55%
70
Outperform
C$8.09B12.0412.32%3.27%-5.01%13.21%
69
Neutral
$973.54M13.3112.20%5.69%-0.72%-9.27%
67
Neutral
C$3.35B71.518.24%15.11%75.40%
63
Neutral
C$359.99M67.028.14%1.07%7.00%110.62%
63
Neutral
C$764.92M24.6849.99%16.25%31.71%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:TCS
TECSYS Inc. J
24.78
-20.29
-45.02%
TSE:OTEX
Open Text
31.22
-9.55
-23.42%
TSE:DSG
The Descartes Systems Group
92.98
-77.31
-45.40%
TSE:KXS
Kinaxis Inc
123.31
-47.74
-27.91%
TSE:ENGH
Enghouse Systems
17.86
-8.61
-32.52%
TSE:DCBO
Docebo
26.11
-34.43
-56.87%

TECSYS Inc. J Corporate Events

Business Operations and Strategy
Tecsys Wins Modern Healthcare Best in Business Award for Supply Chain Excellence
Positive
Jan 13, 2026

Tecsys Inc., a specialist in healthcare-focused supply chain software for functions such as pharmacy inventory management, point-of-use tracking and real-time analytics, has been named a winner in Modern Healthcare’s 2025 Best in Business Awards for supply chain excellence. The recognition underscores Tecsys’s role in shoring up supply chain resilience and visibility for major health systems, helping hospitals ensure critical products are available when and where needed and addressing industry challenges like drug shortages and fragmented demand planning, thereby strengthening its positioning as a key technology partner to leading U.S. health networks and reinforcing investor confidence in its healthcare growth strategy.

The most recent analyst rating on (TSE:TCS) stock is a Hold with a C$32.00 price target. To see the full list of analyst forecasts on TECSYS Inc. J stock, see the TSE:TCS Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
Tecsys Achieves Record Revenue and Growth in Q2 Fiscal 2026
Positive
Dec 3, 2025

Tecsys Inc. reported strong financial results for the second quarter of fiscal 2026, with a 22% increase in SaaS revenue and a 71% rise in adjusted EBITDA. Despite challenges such as U.S. healthcare policy changes and tariff uncertainties, the company achieved record total revenue and professional services growth, demonstrating robust business scalability and execution. Tecsys also expanded its market reach by making its Elite™ software available on AWS Marketplace, providing customers with easier access to its technology. The company maintained its full fiscal 2026 guidance, anticipating continued revenue growth and profitability.

The most recent analyst rating on (TSE:TCS) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on TECSYS Inc. J stock, see the TSE:TCS Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Tecsys Expands Elite™ Platform Access via AWS Marketplace
Positive
Nov 13, 2025

Tecsys Inc. has announced that its Elite™ supply chain platform is now available on AWS Marketplace, enhancing access for healthcare and complex distribution organizations to its enterprise-grade technology. This development aligns with Tecsys’ cloud strategy, offering customers improved visibility, agility, and efficiency in their supply chains, and allowing them to integrate advanced supply chain solutions seamlessly into their existing cloud ecosystems.

The most recent analyst rating on (TSE:TCS) stock is a Buy with a C$39.00 price target. To see the full list of analyst forecasts on TECSYS Inc. J stock, see the TSE:TCS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 04, 2026